VRAX Stock Analysis: Buy, Sell, or Hold?
VRAX - Virax Biolabs Group Limited Ordinary Shares
$0.15
-0.01 (-4.97%)
▼
5d:
-10.41%
30d:
-49.38%
90d:
-12.24%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Jul 01, 2026
7d
Get Alerted When VRAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: VRAX is down 10.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: VRAX is down 10.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: VRAX is currently trading at $0.15, which is considered oversold relative to its 30-day fair value range of $0.16 to $0.26.
Technical Outlook: Technically, VRAX is in a downtrend. The price is currently testing key support at $0.17. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1.00 (+513.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VRAX is in a downtrend. The price is currently testing key support at $0.17. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1.00 (+513.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.16 -
$0.26
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.0%)
- BULLISH: Trading 513.5% below Wall St target ($1.00)
- WARNING: Recommendation downgraded due to -10.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.16 -
$0.26
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.17
Resistance Level
$0.24
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.68
Wall Street Target
$1.00
(+513.5%)
Revenue Growth (YoY)
-67.5%
Share & Embed Analysis
Last updated: June 23, 2026 4:18 PM ET
Data refreshes hourly during market hours. Next update: 5:18 PM
Data refreshes hourly during market hours. Next update: 5:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
